TREATMENT OF PATIENTS WITH ESSENTIAL HYPERTENSION 1-2 GRADE WITH METOPROLOL TARTRATE AND ANALYSIS OF HEART RATE VARIABILITY

Aim. Optimization of therapy in patients with arterial hypertension (HT) 1-2 grade considering heart rate variability (HRV) and efficacy of metoprolol tartrate in long-acting presentation (Egilok retard) during 96 weeks of usage.

Material and methods. 33 patients with mild to moderate HT were treated with Egilok retard. Doses were titrated from 50 to 200mg\daily. If the target level of blood pressure (BP) wasn’t reached, hydrochlorothiazide (12,5-25 mg\daily) was added. Ambulatory BP and ECG monitoring with HRV analysis were carried out before start and after 24, 48, 96 weeks of therapy, echocardiography - after 48 and 96 weeks. Life quality was estimated by four-grade scale.

Results. After 96 weeks 20 patients continued this therapy (60, 6%). Monotherapy provided of BP target level in 13 patients (65%), combined therapy – in 7 (35%). The high patient compliance to the treatment was based on considerable and stable antihypertensive effect, absence of side effects and improvement of life quality during 96 weeks as well as consideration of HRV type. It was suggested to split patients in groups with high, normal and low levels of HRV. It was mostly difficult to reach BP targets in patients with low HRV level. They took combined therapy in 62% (p>0,005). 7 patients demonstrated normalization of disturbed diastolic function which means heart remodelling regress. The longer therapy with Egilok retard showed more significant cardioprotective effect.

Conclusion. Long-term therapy with Egilok retard provides improvement of life quality and significant cardioprotective effect. Beta-blocker therapy can be optimized by consideration of HRV patient type.

1. Кушаковский М.С. Эссенциальная гипертензия. Причины, механизмы, клиника, лечение. СПб.: Фолиант, 2002.

2. Кобалава Ж.Д., Котовская Ю.В., Хирманов В.Н. Артериальное давление в исследовательской и клинической практике. М., 2004.

3. O`Brien E, Staessen J. Normotension and hypertension defined by 24-hour ambulatory blood pressure monitoring. Blood Press. 1995;4(5):266-82.

4. Staessen JA, Bieniaszewski L, Fagart R. Special feature: what is a normal blood pessure in ambulatory monitoring? Nephrol Dial Trasplant. 1996;11(2):241-5.

5. Рогоза А.Н., Никольский В.П., Ощепкова Е.В. Суточное мониторирование АД. Методические вопросы, под ред. Г.Г. Арабидзе и О.Ю. Атькова. М., 1997.

6. Verdecchia P, Schillaci G, Borgioni C, et al. Ambulatory pulse pressure: a potent predictor of total cardiovascular risk in hypertension. J Hypertens 1998;32:983-88.

7. Ивашкин В.Т., Кузнецова Е.И. Оценка риска при АГ и современные аспекты антигипертензивной терапии. РМЖ 1999;7(14):635-42.

8. Task force of the European Society of Cardiology and the North American Society of pacing and electrophysiology. Heart rate variability. Standarts of measurement, physiological interpretation and clinicaluse. Eur Heart J 1996;17:354-81

9. Gang S., Feng W., Haibo R. The relationship between left ventricular hypertrophy, diastolic function and ambulatory blood pressure in patients with borderline hypertension. Chin Med J (Engl) 2000;113:17.

10. Rittoo D, Monaghan M, Sadiq T, et al. Echocardiographic and Doppler evaluation of left ventricular hypertrophy and diastolic function in black and white hypertensive patients. J Hum Hypertens 1990;4:113-5.

11. Олейников В.Э., Буданова В.А., Кулюцин А.В., Белоусов Ю.Б. Эффективность Эгилока Ретард и его влияние на вариабельность сердечного ритма при мягкой и умеренной артериальной гипертензии. Фарматека 2005;20:113-9.

12. White WB, Schulman P, Karimeddini MK, Smith VE. Regression of left ventricular mass is accompanied by improvement in rapid left ventricular filling following antihypertensive therapy with metoprolol. Am Heart J. 1989;117(1):145-50.

13. Wetzchewald D, Klaus D, Garanin G, et al. Regression of left ventricular hypertrophy during long-term antihypertensive treatment - a comparision between felodipine and the combination of felodipine and metoprolol. J Intern Med. 1992;231(3):303-8.

14. Cramer JA. Consequences of intermittent treatment for hypertension: the case for medication compliance and persistence. Am J Manag Care. 1998;4:1563-8.

15. Хохлов А.Л., Лисенкова Л.А., Раков А.А. Анализ факторов, определяющих приверженность к антигипертензивной терапии. Качественная клиническая практика 2003;(4):59-66.

16. Кобалава Ж.Д., Котовская Ю.В., Старостина Е.Г., и др. Проблемы взаимодействия врача и пациента и контроль артериальной гипертонии в России. Основные результаты Российской научно-практической программы АРГУС- 2. Кардиология 2007;3: 38-47.